Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury